Does one voriconazole breakpoint suit all Candida species? [4]

Journal of Clinical Microbiology

Volumn 45, Issue 6, 2007, Pages 2093-

  Arendrup, Maiken Cavling ^a   Denning, David W ^b  

^a STATENS SERUM INSTITUT   (Denmark)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

VORICONAZOLE;

ANTIBIOTIC SENSITIVITY; CANDIDA; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA KRUSEI; CANDIDA PARAPSILOSIS; CANDIDA TROPICALIS; LETTER; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; SPECIES DIFFERENCE;

ANTIFUNGAL AGENTS; CANDIDA; CANDIDIASIS; HUMANS; MICROBIAL SENSITIVITY TESTS; PYRIMIDINES; SPECIES SPECIFICITY; TRIAZOLES;

CANDIDA;

EID: 34250656125     PISSN: 00951137     EISSN: None     Source Type: Journal    
DOI: 10.1128/JCM.00412-07     Document Type: Letter

References (14)

1. Arendrup, M., T. Horn, and N. Frimodt-Moller. 2002. In vivo pathogenicity of eight medically relevant Candida species in an animal model. Infection 30:286-291.
2. Arendrup, M. C., K. Fuursted, B. Gahrn-Hansen, I. M. Jensen, J. D. Knudsen, B. Lundgren, H. C. Schønheyder, and M. Tvede. 2005. Seminational surveillance of fungemia in Denmark: notably high rates of fungemia and numbers of isolates with reduced azole susceptibility. J. Clin. Microbiol. 43:4434-4440.
3. Boyd, A. E., S. Modi, S. J. Howard, C. B. Moore, B. G. Keevil, and D. W. Denning. 2004. Adverse reactions to voriconazole. Clin. Infect. Dis. 39:1241-1244.
4. Colombo, A. L., M. Nucci, B. J. Park, S. A. Nouér, B. Arthington-Skaggs, D. A. da Matta, D. Warnock, and J. Morgan. 2006. Epidemiology of candidemia in Brazil: a nationwide sentinel surveillance of candidemia in eleven medical centers. J. Clin. Microbiol. 44:2816-2823.
5. Denning, D. W., P. Ribaud, N. Milpied, D. Caillot, R. Herbrecht, E. Thiel, A. Haas, M. Ruhnke, and H. Lode. 2002. Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin. Infect. Dis. 34:563-571.
6. Diekema, D. J., S. A. Messer, A. B. Brueggemann, S. L. Coffman, G. V. Doern, L. A. Herwaldt, and M. A. Pfaller. 2002. Epidemiology of candidemia: 3-year results from the emerging infections and the epidemiology of Iowa organisms study. J. Clin. Microbiol. 40:1298-1302.
7. Krause, D. S., J. Reinhardt, J. A. Vazquez, A. Reboli, B. P. Goldstein, M. Wible, and T. Henkel. 2004. Phase 2, randomized, dose-ranging study evaluating the safety and efficacy of anidulafungin in invasive candidiasis and candidemia. Antimicrob. Agents Chemother. 48:2021-2024.
8. Lutsar, I., M. R. Hodges, K. Tomaszewski, P. F. Troke, and N. D. Wood. 2003. Safety of voriconazole and dose individualization. Clin. Infect. Dis. 36:1087-1088.
9. Mora-Duarte, J., R. Betts, C. Rotstein, A. L. Colombo, L. Thompson-Moya, J. Smietana, R. Lupinacci, C. Sable, N. Kartsonis, and J. Perfect. 2002. Comparison of caspofungin and amphotericin B for invasive candidiasis. N. Engl. J. Med. 347:2020-2029.
10. Morrell, M., V. J. Fraser, and M. H. Kollef. 2005. Delaying the empiric treatment of Candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality. Antimicrob. Agents Chemother. 49:3640-3645.
11. Pfaller, M. A., D. J. Diekema, J. H. Rex, A. Espinel-Ingroff, E. M. Johnson, D. Andes, V. Chaturvedi, M. A. Ghannoum, F. C. Odds, M. G. Rinaldi, D. J. Sheehan, P. Troke, T. J. Walsh, and D. W. Warnock. 2006. Correlation of MIC with outcome for Candida species tested against voriconazole: analysis and proposal for interpretive breakpoints. J. Clin. Microbiol. 44:819-826.
12. Reboli, A., C. Rotstein, P. Pappas, J. Schranz, D. Krause, T. Walsh, and Anidulafungin IC Study Group. 2005. Anidulafungin vs. fluconazole for treatment of candidemia and invasive candidiasis (C/IC), abstr. M-718. Abstr. 45th Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology, Washington, DC.
13. Sandven, P., L. Bevanger, A. Digranes, H. H. Haukland, T. Mannsåker, P. Gaustad, and the Norwegian Yeast Study Group. 2006. Candidemia in Norway (1991 to 2003): results from a nationwide study. J. Clin. Microbiol. 44:1977-1981.
14. Viscoli, C., C. Girmenia, A. Marinus, L. Collette, P. Martino, B. Vandercam, C. Doyen, B. Lebeau, D. Spence, V. Krcmery, P. B. De, and F. Meunier. 1999. Candidemia in cancer patients: a prospective, multicenter surveillance study by the Invasive Fungal Infection Group (IFIG) of the European Organization for Research and Treatment of Cancer (EORTC). Clin. Infect. Dis. 28:1071-1079.